MLPA-Based CNV Testing for BRCA1/BRCA2
- Buyer
- HUS Group, the joint authority for Helsinki and Uusimaa, Vantaa
- Country
- Finland
- Estimated value
- —
- Deadline
- 9 Nov 2026, 11:00 CET
- Published
- 8 Oct 2026
- Procedure
- Open procedure
- Contract type
- Supplies
Categories
- 33696500 Laboratory reagents
- 33000000 Medical equipments, pharmaceuticals and personal care products
From the original notice
HUSLAB Laboratory of Genetics at HUS (Helsinki University Hospital) Diagnostic Center is an SFS-EN ISO 15189:2022 accredited laboratory providing diagnostic and follow-up genetic testing services for patients within the Helsinki University Hospital area. The object of the procurement is an MLPA (Multiplex Ligation-dependent Probe Amplification) assay for the detection of copy number variations (CNVs) in BRCA1 and BRCA2 genes, including all reagents, controls, consumables, software, licences and other components required for routine use of the assay and generation of reportable patient…
Only the original notice and the buyer's documents are legally binding.